Sugi Predict
/ Targets
/ EZH2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to EZH2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
PHASE3 | ACTIVE_NOT_RECRUITING |
| Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas |
PHASE1/PHASE2 | UNKNOWN |
| Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer |
PHASE1/PHASE2 | RECRUITING |
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Zandelisib + Tazemetostat in R/R Follicular Lymphoma |
PHASE1/PHASE2 | WITHDRAWN |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an EZH2 Gain-of-function Genetic Mutation |
PHASE2 | WITHDRAWN |
| Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. |
PHASE2 | RECRUITING |
| Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma |
PHASE2 | SUSPENDED |
| Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. |
PHASE1/PHASE2 | WITHDRAWN |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) |
PHASE2 | COMPLETED |
| A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma |
PHASE2 | COMPLETED |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL |
PHASE1/PHASE2 | COMPLETED |
| Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) |
PHASE1/PHASE2 | RECRUITING |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis |
PHASE1/PHASE2 | RECRUITING |
| Tazemetostat and Palbociclib With CPX-351for R/R AML |
PHASE1 | RECRUITING |
| Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction |
PHASE1 | WITHDRAWN |
| CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer |
PHASE1 | RECRUITING |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer |
PHASE1 | RECRUITING |
| PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia |
nan | UNKNOWN |
| Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies |
nan | WITHDRAWN |
| Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma |
nan | UNKNOWN |
| Mechanisms of Immune Deficiency |
nan | UNKNOWN |
| Tazemetostat Expanded Access Program for Adults With Solid Tumors |
nan | NO_LONGER_AVAILABLE |
| Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a EZH2 binder may also engage these)